|
| Press Releases |
|
 |
|
| Thursday, June 22, 2023 |
|
|
Eisai's "Nouknow" Will Continue to be Utilized for Brain Health Assessment as Part of The FY2023 Dementia Examination Project by Tokyo Bunkyo City |
| Eisai Co., Ltd. announced today that brain health checks utilizing "NouKNOW" (pronounced "NOH-NOH"), Eisai's digital tool for self-assessment of cognitive function, will continue to be promoted as part of the FY2023 dementia examination project, conducted by Bunkyo City, Tokyo. more info >> |
|
| Monday, June 12, 2023 |
|
|
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted unanimously that the data from Eisai's Phase 3 Clarity AD clinical trial confirms the clinical benefit of LEQEMBI (lecanemab-irmb) 100 mg/mL injection for intravenous use for the treatment of Alzheimer's disease (AD). more info >> |
|
| Thursday, June 8, 2023 |
|
|
Eisai Files Marketing Authorization Application for Lecanemab as Treatment For Early Alzheimer's Disease in South Korea |
| This application is the first application for lecanemab in Asia outside of Japan and China. Eisai plans to submit additional applications in other Asian countries. more info >> |
|
| Friday, June 2, 2023 |
|
|
Eisai to Present Latest Data on Lemborexant at the 37th Annual Sleep 2023 Meeting |
| Eisai Co., Ltd. announced a total of eight poster presentations, including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO), will be given at the 37th annual meeting of the Associated Professional Sleep Societies (SLEEP 2023), to be held from June 3 to 7, 2023 in Indianapolis, IN, the United States. more info >> |
|
| Friday, May 26, 2023 |
|
|
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma |
| These data will be presented on Monday, June 5 at 11:54 a.m. Central Daylight Time during an oral abstract session at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #4502). more info >> |
|
| Thursday, May 25, 2023 |
|
|
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria |
| Eisai Co., Ltd. has announced that it will grant a total of 625 million yen to the Global Health Innovative Technology Fund ("GHIT Fund") to fund the third phase of its activities, which will take place in the five-year period from FY2023 to FY2027. more info >> |
|
| Wednesday, May 24, 2023 |
|
|
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023 |
| Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO23), which is taking place virtually and in-person in Chicago, Illinois from June 2 to 6. more info >> |
|
| Saturday, May 20, 2023 |
|
|
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Great Britain |
| Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has submitted a Marketing Authorization Application (MAA) for lecanemab, an investigational anti-amyloid beta (Aβ) protofibril antibody, for the treatment of early Alzheimer's disease (mild cognitive impairment due to Alzheimer's disease (AD) and mild AD dementia) with confirmed amyloid pathology in the brain, to the UK Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain. more info >> |
|
| Tuesday, May 16, 2023 |
|
|
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. announced today that Health Canada has accepted a New Drug Submission (NDS) for lecanemab (brand name in the U.S.: LEQEMBI), an investigational anti-amyloid beta (Abeta) protofibril* antibody, for the treatment of early Alzheimer's disease (mild cognitive impairment due to Alzheimer's disease (AD) and mild AD dementia) with confirmed amyloid pathology in the brain. more info >> |
|
| Monday, May 8, 2023 |
|
|
Eisai Enters Into Joint Development Agreement with Blissbio for Antibody Drug Conjugate BB-1701 with Option Rights for Strategic Collaboration |
| Eisai Co., Ltd. announced today that it has entered into a joint development agreement with Bliss Biopharmaceutical (Hangzhou) Co., Ltd., for BB-1701, an antibody-drug conjugate (ADC) with option rights for a strategic collaboration. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
WiseChain.io Unveils AI-Powered Social Trading and Tailored Investment Solutions for Canadians and Seniors
Mar 29, 2025 11:00 HKT/SGT
|
|
|
Mobvoi 2024 Annual Results Announcement 
Mar 29, 2025 02:19 HKT/SGT
|
|
|
Dynasty's Profit Attributable to Owners of The Company Increases by 57%
Mar 29, 2025 00:42 HKT/SGT
|
|
|
Hua Medicine Announces 2024 Annual Results
Mar 28, 2025 21:51 HKT/SGT
|
|
|
Analogue FY2024 Revenue Rose to HK$6,450 Million with Adjusted Profit Attributable to Owners of the Company Increased to HK$206 Million
Mar 28, 2025 21:21 HKT/SGT
|
|
|
Nissin Foods Announces 2024 Annual Results
Mar 28, 2025 20:56 HKT/SGT
|
|
|
Accelerated Transformation of New Quality Productive Forces with Growing Efficacy in Sci-Tech Innovation Layout
Mar 28, 2025 18:21 HKT/SGT
|
|
|
WL Delicious Announced 2024 Annual Results
Mar 28, 2025 16:55 HKT/SGT
|
|
|
Leading the Future with Reform and Innovation, Embarking on a New Chapter of Global Development
Mar 28, 2025 16:05 HKT/SGT
|
|
|
Mitsubishi Corporation, ADM Sign Non-Binding MOU, Form Strategic Alliance
Mar 28, 2025 16:29 JST
|
|
|
CIMC Group Announces 2024 Annual Results
Mar 28, 2025 14:32 HKT/SGT
|
|
|
Tingyi (Cayman Islands) Holding Corp. 'Dual-wheel Drive of Product Structure & Operational Efficiency' to Enhance Profitability in 2024 with GPM Improving to 33.1% and EBITDA Rising 17.3%
Mar 28, 2025 13:58 HKT/SGT
|
|
|
Sonimedi Captivates the European Beauty Market - Wins 'Best Hair Product' Award at Cosmoprof Bologna 2025
Mar 28, 2025 13:46 HKT/SGT
|
|
|
Everbright Grand China Assets Recorded Revenue of RMB 45.9 Million in 2024
Mar 28, 2025 13:27 HKT/SGT
|
|
|
Dubai AI Festival returns for highly anticipated second edition as part of the inaugural Dubai AI Week
Mar 28, 2025 12:35 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
